Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, r...
Saved in:
| Main Authors: | M. V. Shestakova, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. Y. Demidova, A. M. Mkrtumyan, N. A. Petunina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-07-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of the effectiveness and safety of fixed-dose combination of alogliptin and pioglitazone in real clinical practice: results of the PROsperity study
by: M. V. Shestakova, et al.
Published: (2025-05-01) -
Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment
by: S. К. Zyryanov, et al.
Published: (2025-02-01) -
Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes
by: V. V. Salukhov, et al.
Published: (2024-03-01) -
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy
by: Aneta Cinakova, et al.
Published: (2025-01-01) -
Therapeutic Potential and Challenges of Pioglitazone in Cancer Treatment
by: Maria Vasileiou, et al.
Published: (2025-02-01)